glp 1 drugs for weight loss insurance coverage Insurer strategies to control costs associated with MCT2D | 2023 Updates to
Description
Clinical trials for GLP-1 agonists have reported musculoskeletal side effects such as back pain and muscle pain in a small percentage of participants, but joint pain specifically has not emerged as a consistent or significant adverse event across the class
1,220 PKA, a key enzyme, phosphorylates various target proteins, affecting their activity and function, which in turn promotes insulin synthesis and secretion
doi.org/10.1111/dom.16275 3 Neeland IJ, Linge J, Birkenfeld AL
However, the results regarding postprandial GLP-1 secretion and fasting GLP-1 between individuals with versus without T2DM are inconsistent
